Table 5.

Persistence by level of historical adherence.

CohortNo. Prescription/ InjectionsAdherence Level to Oral MedicationsAdjusted HR (Tofacitinib to the bDMARD)Adherence Level to Injectable MedicationsAdjusted HR (Tofacitinib to the bDMARD)
New users≥ 1High0.95 (0.83–1.08)High1.22 (0.90–1.66)
  Low1.33 (1.17–1.52)Low1.18 (0.84–1.66)
 ≥ 2High0.82 (0.70–0.96)High0.88 (0.60–1.30)
  Low1.15 (0.98–1.35)Low1.02 (0.65–1.56)
Switchers≥ 1High0.86 (0.77–0.97)High0.91 (0.80–1.04)
  Low0.91 (0.80–1.02)Low0.86 (0.73–1.02)
 ≥ 2High0.86 (0.77–0.96)High0.76 (0.67–0.86)
  Low0.88 (0.79–0.99)Low0.85 (0.74–0.98)
  • HR are not shown for patients with unknown adherence; those patients were not treated with antirheumatic, antihypertensive, and/or oral antidiabetic medications in the 2 years before cohort entry or had a single prescription for each medication.

  • HR for discontinuation (95% CI), where the bDMARD is the reference. HR of discontinuation of tofacitinib compared with bDMARD were estimated from Cox regression models with an interaction term between medication and adherence level. Discontinuation was assigned based on a medication-free interval of 90 days or on switching. Values < 1 favor tofacitinib (longer persistence). bDMARD: biological disease-modifying antirheumatic drug.